Studies show remote patient monitoring technology better predicts cough exacerbations to ultimately improve quality of life and reduce healthcare costs for patients with chronic cough.
Wilmington, Del., July 19, 2023 -- Hyfe, Inc., the global leader in AI-powered cough detection, tracking and classification, announces today the launch of its novel remote patient monitoring (RPM) program that is on track to provide an easy-to-use cough monitoring capability for virtual hospitals, remote care and telehealth programs across the U.S. The integration of Hyfe’s technology has the potential to enable providers to remotely monitor and treat patients with chronic cough and pulmonary diseases like COPD and asthma to improve quality of life, reduce healthcare costs and ease the burden on health systems.
Cough is the most common symptom for which patients seek medical care and an estimated 12 million adults in the United States – or about 5% of the adult population – have chronic cough. Until now, this symptom has not been quantified in any meaningful way, and has historically been extremely difficult to accurately measure and monitor. Hyfe’s AI-powered technology has been shown in clinical trials to accurately, passively and remotely detect, monitor, and report the number of times a person coughs. By giving RPM providers the ability to track longitudinal cough data, it will ultimately enable patients to better understand their cough and have more informed conversations with their providers. .
Cough is one of the most common reasons patients seek health care and exacerbations are a leading cause of hospital and health clinic visits. Using RPM, a patient will receive advanced notice of an exacerbation up to 3.5 days in advance, according to a study published in the National Library of Medicine. Hyfe’s RPM capability can help track increases in cough leading up to an exacerbation event in order to provide treatment earlier and prevent hospitalizations. Better predicting these events using RPM would enhance quality of life and reduce costs for patients, while also improving the effectiveness and efficiency of health systems.
“We’re excited to be on the forefront of building this capability for remote patient monitoring and believe that once FDA cleared, cough will be an inevitable biomarker to monitor in the future, just like temperature and blood pressure, and become essential for assessing health and medical conditions,” said Joe Brew, Co-founder and CEO of Hyfe. “We are already having conversations with clinics and technology companies who are eager to plan how to use RPM for cough tracking. We’re looking forward to bringing this technology to the pulmonary space and assisting patients and providers in making informed and thoughtful medical decisions.”
Hyfe’s cough monitoring technology is currently available as a wellness app and not yet FDA cleared as a medical device.
For more information, visit hyfe.ai.
About Hyfe
Hyfe, Inc. is the global leader in AI-powered cough detection and classification that provides insight into cough patterns and correlations that can greatly improve treatment and prevention. With more than 700 million samples, Hyfe maintains the largest cough dataset in the world enabling the building of powerful models to track, manage and diagnose respiratory illnesses. Hyfe provides platforms and data for pharmaceutical companies, medical researchers, government agencies, health care providers and patients and has partnerships with leading academic institutions including Johns Hopkins University and the University of California at San Francisco. The company was founded in 2020 and is headquartered in Wilmington, Delaware. More information is available at Hyfe.ai, on social media @hyfeapp and LinkedIn at /hyfe.
Contact:
AM PR for Hyfe AI
.JPG)
.jpg)